11 results about "Symptomatic relief" patented technology

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a new use of Xintong oral liquid, and particularly to an application of the Xintong oral liquid in treating neurosis. The Xintong oral liquid is mainly prepared from Huangqi, Dangshen, Maidong, Heshouwu, Yinyangheuo, Gegen, Dangui, Danshen, Zaokesheng, Haizao, Kunkunbu, Muli and Zhishi. The Xintong oral liquid can improve the symptom of anhedonia of an anxiety model rat, relieve the phenomenon of a decrease in the exercise behavior frequency of the anxiety model rat, obviously increase the content level of 5- HT, DA and NE neurotransmitters in the hippocampus of the rat, and effectively treat anxiety.

The horizontal type cervical traction bed comprises a bed body, the head position of the bed body is provided with a head movable bed plate capable of sliding along an arc-shaped track, and the head movable bed plate is connected with the bed body through an arc-shaped sliding rail mechanism arranged below the head movable bed plate; the arc-shaped sliding rail mechanism can be movably adjusted according to the use requirements of a patient; a neck fixing mechanism is arranged above the head moving bed board and used for fixing the head of a patient. According to the horizontal type cervical vertebra traction bed adapting to the physiological curvature of the cervical vertebra, through the unique arc-shaped traction groove design, the natural physiological curvature of the cervical vertebra of the human body can be perfectly matched; in the traction process, traction force can be evenly distributed according to the bending shape of the cervical vertebra and accurately acts on each vertebral body, intervertebral space is effectively expanded, compression of the intervertebral disc on nerve roots and spinal cords is remarkably relieved, and compared with traditional traction equipment, the precision and effectiveness of traction treatment are greatly improved, and a more remarkable symptom relieving effect is brought to a patient.

This invention relates to the field of biomedical materials technology, and more particularly to a flexible patch for treating nervous system diseases and its preparation method. It comprises: a flexible, breathable substrate composed of silk fibroin nanofibers, and drug-loaded nanoparticles loaded within the substrate; the drug-loaded nanoparticles are encapsulated with chitosan and contain levodopa and copper oxide nanoenzymes; the silk fibroin nanofibers are annealed with ethanol to form a controllable degradation structure, achieving self-adhesion and continuous drug release in a humid environment. This patch can simultaneously achieve stable delivery of dopamine and scavenging of reactive oxygen species, thus addressing the motor complications and neurooxidative damage caused by fluctuations in blood drug concentration in traditional Parkinson's disease treatment, achieving a dual synergistic treatment of symptom relief and neuroprotection.

The present invention relates to a system and method for managing neurological and psychological disorders, with a specific focus on Obsessive-Compulsive Disorder (OCD). The invention integrates pharmacotherapy, Deep Transcranial Magnetic Stimulation (Deep TMS), and Exposure and Response Prevention (ERP) therapy into a unified framework that addresses the chemical, neurological, and behavioural dimensions of OCD. The system utilizes advanced data analysis and machine learning algorithms to dynamically customize interventions based on patient-specific profiles, ensuring optimal therapeutic efficacy and reduced side effects. The System includes real-time data-driven adjustments, high-intensity engagement protocols, remote monitoring for long-term management, and scalable group therapy capabilities. The system also incorporates advanced neuromodulation technologies and compressed ERP techniques to accelerate behavioural restructuring and neural circuit modulation. By leveraging the synergy between these modalities, the invention provides a holistic and versatile solution for improving patient outcomes, ensuring sustained symptom relief and enhanced quality of life.

The invention relates to application of a CXCL14 recombinant protein in preparation of a medicine for preventing or treating radiation enteritis, and belongs to the technical field of biomedicine. Excessive inflammation is inhibited by regulating chemotaxis and pro-inflammatory polarization of key immune cells such as macrophages. The CXCL14 recombinant protein directly acts on intestinal epithelial cells and crypt stem cells to promote intestinal villus repair and crypt regeneration, so that the intestinal barrier is structurally recovered. The specific value of intestinal villus length / crypt depth is remarkably increased, and it is proved that the CXCL14 recombinant protein can achieve functional healing instead of symptom relieving.

The invention relates to the technical field of medical instruments, in particular to a transanal probiotic colonization enema device and method.The transanal probiotic colonization enema device comprises a transparent scale liquid storage bag and an annular bag belt, the outer wall of the transparent scale liquid storage bag is sleeved with the annular bag belt, and the inner wall of the annular bag belt is fixedly connected with a constant-temperature heater; the outer wall of the transparent scale liquid storage bag is wrapped with a paraffin-based composite layer, the lower surface of the transparent scale liquid storage bag is fixedly connected with a medical silica gel catheter through a Luer taper, gastric acid and bile inactivation barriers are bypassed through rectal administration, the survival rate of probiotics is greatly increased, the probiotics directly reach the colon diseased region in a targeted mode, and the survival rate of the probiotics is increased. High-concentration florae are in accurate contact with intestinal mucosa, the colonic colonization rate is increased, the symptom relieving period is shortened, the device is easy and convenient to assemble and suitable for families and basic medical scenes, double leakage prevention is achieved through the annular bag, the funnel-shaped abutting piece and the leakage-proof and backflow-proof valve, leakage is eradicated, tissue damage is reduced through the arc-shaped tip design, and the use comfort is improved through self-adaptive sealing.

The invention relates to the field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating fever symptoms of dengue fever. The composition is prepared by compatibility of cyperus rotundus, pseudo-ginseng, sargentgloryvine stem, sargentgloryvine stem, dutchmanspipe root, costus root, Zhenmei borneol and fresh pteris multifida according to a specific proportion, and quick fever abatement and symptom relief are realized by accurately controlling a medicinal material processing technology, a grinding mode and a mixing taking condition. Rapid control of dengue fever is achieved through multi-target intervention (clearing away heat and toxic materials, promoting blood circulation to remove blood stasis and regulating qi and blood), the problems of liver and kidney toxicity and drug resistance of chemical drugs are avoided, and the traditional Chinese medicine composition is particularly suitable for emergency treatment in areas lack of medical resources and has the advantages of being high in safety, easy and convenient to prepare and high in adaptability.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from astragalus membranaceus, prepared rehmannia roots, radix polygoni multiflori preparata, radix puerariae, safflower carthamus, radix paeoniae rubra, earthworms, scorpions, gastrodia elata, rhizoma acori graminei and ligusticum wallichii. The formula design is based on the compound pathogenesis of qi deficiency and blood stasis, kidney essence deficiency and phlegm and blood stasis of cardiovascular and cerebrovascular diseases, all the components respectively correspond to the core effects of tonifying qi and replenishing essence, promoting blood circulation to remove meridian obstruction, calming the liver, relieving dizziness and the like, and a multi-target synergistic effect is formed through strict compatibility of monarch, minister, assistant and guide. The synergetic balance can be destroyed if any component is replaced or deleted or the dosage of the component exceeds a limited range, so that the comprehensive curative effect of pathological intervention and symptom relief cannot be considered at the same time.

This invention discloses a urinary stone-dissolving instrument based on the fusion of electrotherapy and mechanical vibration technology. This invention relates to the field of lithotripsy technology and includes a control box. The control box contains a stone-dissolving component and a storage component. The stone-dissolving component includes electrodes, a vibrating rod, a limiting rod, and a plug. The side of the electrode is connected to one end of the plug, and the inner wall of the vibrating rod is threadedly connected to the outer periphery of the plug. Both the electrode and the vibrating rod are electrically connected to the control box via the plug. The advantages of this invention are: the complementary combination of electrotherapy and vibration technologies improves the efficiency of urinary stone dissolving. During treatment, electrotherapy continuously exerts analgesia and vasodilatory effects, while vibration focuses on promoting dissolving. When vibration causes spasmodic pain due to stone movement, electrotherapy can relieve pain and improve patient tolerance. Simultaneously, continuous blood circulation provides sufficient nutrition to the ureter, reducing traction damage to tissues caused by vibration, ultimately achieving simultaneous improvement in stone dissolving efficiency and symptom relief.

This invention, entitled "Application of Akkermansia myxophilus in Enhancing Immunity and Preparing Products for the Prevention, Treatment, and / or Adjunctive Treatment of Rhinitis," belongs to the field of microbial technology. Existing treatments for rhinitis suffer from problems such as short-lasting symptom relief, limited single-effect anti-inflammatory properties, and a tendency to cause side effects. To address these issues, this invention provides a novel Akkermansia myxophilus strain, AKK IMMU, which was deposited on November 3, 2025, at the Guangdong Provincial Center for Microbial Culture Collection (GDMCC No: 67192). This strain significantly improves nasal mucosal pathological damage in rhinitis model mice, regulates serum oxidative stress indicators, and modulates inflammatory factors in lung tissue.

The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same. The present invention further relates to the combination of compounds useful for the therapeutic use. The present invention relates to the pharmaceutical composition comprising the compound and combination of compounds useful for treatment of urinary bladder pain, the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.